Tyra Biosciences (TYRA) Net Cash Flow (2020 - 2026)

Tyra Biosciences (TYRA) has 7 years of Net Cash Flow data on file, last reported at $7.6 million in Q1 2026.

• Quarterly Net Cash Flow fell 13.56% year-over-year to $7.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$15.8 million (up 89.74% YoY) and the FY2025 annual result came in at -$14.6 million, down 142.93% from the prior year.
• Net Cash Flow slipped to $7.6 million in Q1 2026, from $15.4 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $196.4 million in Q1 2024 to a low of -$157.6 million in Q4 2023.
• A 5-year average of -$12.7 million and a median of -$9.5 million in 2023 frame the typical range for Net Cash Flow.
• The widest YoY moves for Net Cash Flow: up 2164.34% in 2024, down 1567.48% in 2024.
• Tracing TYRA's Net Cash Flow over 5 years: stood at -$12.0 million in 2022, then plunged by 1213.94% to -$157.6 million in 2023, then surged by 92.43% to -$11.9 million in 2024, then surged by 229.43% to $15.4 million in 2025, then plunged by 50.97% to $7.6 million in 2026.
• The last three Net Cash Flow figures came in at $7.6 million (Q1 2026), $15.4 million (Q4 2025), and -$36.5 million (Q3 2025), per Business Quant data.